VYNE Therapeutics Inc.

Historical 13F Holders

Symbol
VYNE
CUSIP
92941V308
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 92941V308 since 12/18/2024, newest first.

Filer % of Class Filed
Zhang Xiaofan 13G/A Amendment 2 7/17/2026
Event 6/8/2026
Zhang Xiaofan 13G/A Amendment 1 7/14/2026
Event 7/13/2026
Zhang Xiaofan 13G 5.6% 6/15/2026
Event 6/8/2026
Nantahala Capital Management, LLC 13G
6.0% 5/15/2026
Event 3/31/2026
Eventide Asset Management, LLC 13G/A Amendment 2
0% 11/14/2025
Event 9/30/2025
Cormorant Asset Management, LP 13G/A Amendment 4
0% 11/14/2025
Event 9/30/2025
Citadel Advisors LLC 13G/A Amendment 3
0% 11/14/2025
Event 9/30/2025
Eventide Asset Management, LLC 13G/A Amendment 1
10.0% 8/14/2025
Event 6/30/2025
Cormorant Asset Management, LP 13G/A Amendment 3
8.2% 8/14/2025
Event 6/30/2025
Cormorant Asset Management, LP 13G/A Amendment 2
10.0% 5/19/2025
Event 3/31/2025
Cormorant Asset Management, LP 13G/A Amendment 1
0% 5/15/2025
Event 3/31/2025
Citadel Advisors LLC 13G/A Amendment 2
7.2% 5/15/2025
Event 3/31/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 46 16.4 M $10.7 M
2026 Q1 46 15.4 M $9.20 M
2025 Q4 43 9.18 M $5.32 M
2025 Q3 34 3.93 M $1.32 M
2025 Q2 46 8.05 M $13.3 M
2025 Q1 38 7.11 M $11.4 M
2024 Q4 36 7.49 M $24.9 M
2024 Q3 35 7.67 M $14.9 M
2024 Q2 33 7.94 M $16.0 M
2024 Q1 34 7.80 M $22.8 M
2023 Q4 35 7.87 M $18.3 M
2023 Q3 21 360 k $1.45 M
2023 Q2 20 376 k $1.53 M
2023 Q1 22 336 k $1.03 M